RE:New name, new listing, same old Gilles"They have 3 or four quarters of runway and for a CEO that hasnt delivered on single thing, not one thing in 15 years..."
You haven't even seen the plan. This company is asset rich; including with "transformational" assets according to Ronnie Miller. With that the company has options; especially as assets hit key milestones. The company also has near-term revenue opportunities and is integrating the two companies with an eye to cost savings and synergies. A "fulsome" update is expected "shortly". The company's goal remains...
"Our goal remains to focus our resources and cash on those programs and products that we believe will propel the Company to its next phase of growth as a diversified biopharmaceutical company,” added Gilles Gagnon, Chief Executive Officer of the Company." Gilled Gagnon